CLAIMS

What is claimed:

1. Use of about 1.0% tapinarof topical cream composition in the manufacture of a medicament for treating or preventing atopic dermatitis in a subject in need thereof, wherein the medicament is to be administered to an affected area of the subject once daily for a period of time of at least 8 weeks;

wherein, after the period of time, the subject has:

at least a 2-grade improvement in vIGA-AD score from baseline, and

an vIGA-AD score of 0;

a reduction in a PP-NRS score ≥ 4 points from baseline during the period of time; and

wherein the plasma concentration of tapinarof in the subject is below 50 pg/mL while applying the medicament.

2. The use of claim 1, wherein the subject has an improvement in an EASI score of about 75% from baseline during the period of time.

3. The use of claim 1, wherein the subject is at least 12 years old.

4. The use of claim 1, wherein the subject is at least 2 years old.

5. The use of claim 1, wherein the subject does not experience an adverse event during the period of time, wherein the adverse event is selected from the group consisting of contact dermatitis, folliculitis, headache, and a combination thereof.

6. The use of claim 1, wherein the subject has an affected BSA of about 43%.

7. The use of claim 1 wherein the subject as an affected BSA of up to about 90%.

8. The use of claim 1, wherein the subject has a patient-reported Local Tolerability Score (LTS) < 1.

9. The use of claim 1, wherein the subject does not experience burning, stinging, or local irritation at the affected area.

10. The use of claim 1, wherein the affected area comprises a sensitive area, an intertriginous area, or a combination thereof.

11. Use of about 1.0% tapinarof topical composition in the manufacture of a medicament for treating atopic dermatitis in a subject from 2-17 years old, wherein

the subject has a vIGA-AD™ score of 3 or greater and the subject has been diagnosed with atopic dermatitis having a percent body surface area (BSA) affected of ≥25% of the BSA,

the medicament is to be topically administered to affected areas of the subject once a day for about 4 weeks,

after the medicament has been topically administered, an Investigator Global Assessment (IGA) score of the subject is improved by 2 grades or has improved to a score of 0 or 1, and the adolescent subject has a maximum observed plasma tapinarof concentration (C_{max}) of <50 pg/mL.

12. The use of claim 11, wherein the topical composition is an oil-in-water emulsion.

13. The use of claim 12, wherein the oil phase of the oil-in-water emulsion is comprised of medium chain triglycerides, propylene glycol, non-ionic emulsifying wax, diethylene glycol monoethyl ether, polyoxyl stearyl ether-2, polysorbate 80, polyoxyl stearyl ether-20, benzoic acid, and butylated hydroxytoluene.

14. The use of claim 12, wherein the water phase of the oil-in-water emulsion is comprised of sodium citrate, edetate disodium, citric acid monohydrate, and water.

15. The use of claim 11, wherein the topical administration includes application to the affected area of the skin selected from the group consisting of body, arms, legs, back, chest, buttocks, neck, scalp, fingernails, toenails, and combinations thereof.

16. The use of claim 11, wherein the subject has been diagnosed with atopic dermatitis having a percent body surface area (BSA) affected of about 26% to about 90%.

17. The use of claim 11, wherein the subject is 12-17 years of age and has been diagnosed with atopic dermatitis having a percent body surface area (BSA) affected of ≥25%.

18. The use of claim 11, wherein the subject is 2-11 years of age and has been diagnosed with atopic dermatitis having a percent body surface area (BSA) affected of ≥35%.

19. The use of claim 11, wherein the subject has been diagnosed with atopic dermatitis having an Investigator Global Assessment (IGA) score of greater than or equal to 3.

20. The use of claim 11, further comprising an improvement of one or more symptoms of atopic dermatitis as measured according to an assessment selected from the group consisting

of Investigator Global Assessment (IGA) score, daily Itch/Pruritus numeric rating scale, Eczema Area and Severity Index (EASI), percent body surface area (BSA) affected, sleep quality, dry/rough skin, red-discolored skin, flaky skin, visual analogue scale (VAS) for sleep, visual analogue scale (VAS) for itch, and patient reported outcomes.

21. The use of claim 20, wherein the Itch/Pruritus numeric rating scale is improved by ≥4 points after the medicament has been topically administered.

22. The use of claim 20, wherein the Eczema Area and Severity Index (EASI) is improved by greater than or equal to 50% or is improved by greater than or equal to 75% after the medicament has been topically administered.

23. The use of claim 20, wherein the percent body surface area (BSA) affected is decreased to less than 20% after the medicament has been topically administered.

24. The use of claim 20, wherein the patient reported outcomes demonstrate that subject's impression of symptom severity was improved after the medicament has been topically administered, and wherein the symptoms are selected from the group consisting of itchy skin, red/discolored skin, bleeding, weeping or oozing skin, cracked skin, scaly skin, flaky skin, dry or rough skin, painful skin, burning skin, and disturbed sleep.